Regulus Therapeutics announced interim results from one of its ongoing phase 2 studies of RG-101, an anti-miR targeting miR-122, which indicated that the drug in combination with Harvoni, Olysio or Daklinza, was safe and effective for reducing hepatitis C virus infection over 4 weeks.
